Ralliant’s (RAL) “Buy” Rating Reiterated at Truist Financial

Ralliant (NYSE:RAL)‘s stock had its “buy” rating reissued by investment analysts at Truist Financial in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $68.00 price target on the stock, up from their previous price target of $53.00. Truist Financial’s target price points to a potential upside of 12.37% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Royal Bank Of Canada restated a “sector perform” rating and set a $64.00 price objective on shares of Ralliant in a report on Wednesday. Barclays raised their price objective on Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday. Citigroup restated a “buy” rating on shares of Ralliant in a report on Wednesday. Finally, Zacks Research upgraded Ralliant from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $57.70.

Ralliant Trading Up 2.3%

Shares of RAL stock traded up $1.35 during mid-day trading on Wednesday, hitting $60.51. 1,018,838 shares of the company’s stock were exchanged, compared to its average volume of 1,700,286. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $62.35. The stock has a 50-day simple moving average of $44.59 and a two-hundred day simple moving average of $47.19. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38. The stock has a market cap of $6.77 billion and a price-to-earnings ratio of 30.68.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.08. The business had revenue of $534.60 million for the quarter. The business’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities analysts expect that Ralliant will post 2.37 EPS for the current fiscal year.

Insider Buying and Selling

In other Ralliant news, SVP Karen M. Bick sold 5,485 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $45.00, for a total value of $246,825.00. Following the transaction, the senior vice president directly owned 46,756 shares of the company’s stock, valued at $2,104,020. This trade represents a 10.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Institutional Trading of Ralliant

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP increased its position in shares of Ralliant by 60.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,314,834 shares of the company’s stock worth $54,669,000 after acquiring an additional 496,171 shares during the last quarter. Scarborough Advisors LLC purchased a new stake in shares of Ralliant during the first quarter worth about $56,000. KBC Group NV increased its position in shares of Ralliant by 0.7% during the first quarter. KBC Group NV now owns 125,583 shares of the company’s stock worth $5,223,000 after acquiring an additional 882 shares during the last quarter. Swiss National Bank increased its position in shares of Ralliant by 0.4% during the first quarter. Swiss National Bank now owns 223,200 shares of the company’s stock worth $9,283,000 after acquiring an additional 900 shares during the last quarter. Finally, Twin Capital Management Inc. purchased a new stake in shares of Ralliant during the first quarter worth about $916,000.

Key Headlines Impacting Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Ralliant beat Q1 expectations, reporting $0.57 in adjusted EPS versus the $0.49 consensus, with revenue of $534.6 million rising 11% year over year. Ralliant earnings report and conference call
• Positive Sentiment: The company raised its 2026 outlook, guiding for adjusted EPS of $2.53-$2.69 and Q2 EPS of $0.58-$0.64, both above analyst estimates, which suggests management sees continued momentum. Ralliant productivity savings and guidance article
• Positive Sentiment: Ralliant also announced a $100 million accelerated share repurchase, a capital return move that can support earnings per share and signal confidence in the stock’s valuation. Ralliant share repurchase announcement
• Positive Sentiment: Management said it expects $50 million to $60 million in productivity savings by 2028, reinforcing margin improvement potential and longer-term earnings growth. Ralliant productivity savings article

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.